Stock Analysis

When Can We Expect A Profit From Crossject Société Anonyme (EPA:ALCJ)?

ENXTPA:ALCJ
Source: Shutterstock

With the business potentially at an important milestone, we thought we'd take a closer look at Crossject Société Anonyme's (EPA:ALCJ) future prospects. Crossject Société Anonyme develops needle-free injection systems in France. On 31 December 2023, the €80m market-cap company posted a loss of €8.6m for its most recent financial year. As path to profitability is the topic on Crossject Société Anonyme's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

See our latest analysis for Crossject Société Anonyme

Crossject Société Anonyme is bordering on breakeven, according to some French Medical Equipment analysts. They expect the company to post a final loss in 2024, before turning a profit of €19m in 2025. Therefore, the company is expected to breakeven just over a year from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 83%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
ENXTPA:ALCJ Earnings Per Share Growth May 30th 2024

Underlying developments driving Crossject Société Anonyme's growth isn’t the focus of this broad overview, but, take into account that generally a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we would like to bring into light with Crossject Société Anonyme is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Crossject Société Anonyme, so if you are interested in understanding the company at a deeper level, take a look at Crossject Société Anonyme's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:

  1. Valuation: What is Crossject Société Anonyme worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Crossject Société Anonyme is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Crossject Société Anonyme’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Valuation is complex, but we're helping make it simple.

Find out whether Crossject Société Anonyme is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.